Statement of Organization, Functions, and Delegations of Authority, 38158 [2024-09382]
Download as PDF
<![CDATA[
38158
Federal Register / Vol. 89, No. 89 / Tuesday, May 7, 2024 / Notices
The reorganization retitled OCE as the
Office of Communication, Information
Disclosure, Training, and Education
(OCITE); abolished the Digital
Communication Media Staff; established
the Office of Communication and
Content Development (OCCD) and the
Office of Training and Education (OTE)
within OCITE, established the Division
of Digital Communication and
Marketing (DDCM) within OCCD, and
realigned the existing divisions to the
new offices.
DCCE. ORGANIZATION. CDRH’s
OCITE is headed by the Director, and
includes the following:
Office of Communication, Information
Disclosure, Training, and Education
(DCCE)
Program Management Operations Staff
(DCCE1)
Office of Communication and Content
Development (DCCEE)
Division of Communication (DCCEEA)
Division of Information Disclosure
(DCCEEB)
Division of Digital Communication and
Marketing (DCCEEC)
Office of Training and Education
(DCCEF)
Division of Employee Training and
Development (DCCEFA)
Division of Industry and Consumer
Education (DCCEFB)
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
khammond on DSKJM1Z7X2PROD with NOTICES
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete SMG can find it on FDA’s
website at: https://www.fda.gov/
AboutFDA/ReportsManualsForms/Staff
ManualGuides/default.htm.
(Authority: 44 U.S.C. 3101).
Xavier Becerra,
Secretary, Department of Health and Human
Services.
[FR Doc. 2024–09381 Filed 5–6–24; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
15:55 May 06, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions,
and Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA), Center for
Devices and Radiological Health’s
(CDRH), Office of Product Evaluation
and Quality (OPEQ) has modified their
organizational structure. The new
organizational structure was approved
by the Secretary of Health and Human
Services on December 21, 2023, and it
became effective on January 22, 2024.
FOR FURTHER INFORMATION CONTACT:
Yashika Rahaman, Director, Office of
Planning, Evaluation and Risk
Management, Office of Finance, Budget,
Acquisitions and Planning, Food and
Drug Administration, 4041 Powder Mill
Rd., Beltsville, MD 20705–4304, 301–
796–3843.
SUMMARY:
I. Introduction
Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970, 60 FR 56606, November 9, 1995,
64 FR 36361, July 6, 1999, 72 FR 50112,
August 30, 2007, 74 FR 41713, August
18, 2009, 76 FR 45270, July 28, 2011,
and 84 FR 22854, May 20, 2019) is
amended to reflect the reorganization of
the CDRH OCE.
The reorganization of OPEQ impacted
the OPEQ’s Office of Clinical Evidence
and Analysis (OCEA) and the OPEQ’s
Office of Health Technology IV (OHT
IV). OCEA established the Division of
Clinical Evidence and Analysis IV and
the Division of Clinical Evidence and
Analysis V. OHT IV established the
Division of Health Technology IV C.
DCCFB. ORGANIZATION. CDRH’s
OPEQ OCEA is headed by the Director,
and includes the following:
Office of Clinical Evidence and Analysis
(DCCFB)
Division of Clinical Evidence and
Analysis I (DCCFBA)
Division of Clinical Evidence and
Analysis II (DCCFBB)
Division of Clinical Evidence and
Analysis III (DCCFBC)
Division of Clinical Evidence and
Analysis IV (DCCFBD)
Division of Clinical Evidence and
Analysis V (DCCFBE)
PO 00000
Frm 00141
Fmt 4703
Sfmt 4703
DCCFF. ORGANIZATION. CDRH’s
OPEQ OHT IV is headed by the Director,
and includes the following:
Office of Health Technology IV (DCCFF)
Division of Health Technology IV A
(DCCFFA)
Division of Health Technology IV B
(DCCFFB)
Division of Health Technology IV C
(DCCFFC)
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete SMG can find it on FDA’s
website at: https://www.fda.gov/
AboutFDA/ReportsManualsForms/Staff
ManualGuides/default.htm.
(Authority: 44 U.S.C. 3101).
Xavier Becerra,
Secretary, Department of Health and Human
Services.
[FR Doc. 2024–09382 Filed 5–6–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–1917]
Fresenius Kabi USA, LLC, et. al.;
Withdrawal of Approval of 12
Abbreviated New Drug Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
withdrawing approval of 12 abbreviated
new drug applications (ANDAs) from
multiple applicants. The applicants
notified the Agency in writing that the
drug products were no longer marketed
and requested that the approval of the
applications be withdrawn.
DATES: Approval is withdrawn as of
June 6, 2024.
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
SUMMARY:
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 89, Number 89 (Tuesday, May 7, 2024)]
[Notices]
[Page 38158]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09382]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions, and Delegations of
Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA), Center for Devices
and Radiological Health's (CDRH), Office of Product Evaluation and
Quality (OPEQ) has modified their organizational structure. The new
organizational structure was approved by the Secretary of Health and
Human Services on December 21, 2023, and it became effective on January
22, 2024.
FOR FURTHER INFORMATION CONTACT: Yashika Rahaman, Director, Office of
Planning, Evaluation and Risk Management, Office of Finance, Budget,
Acquisitions and Planning, Food and Drug Administration, 4041 Powder
Mill Rd., Beltsville, MD 20705-4304, 301-796-3843.
I. Introduction
Part D, Chapter D-B, (Food and Drug Administration), the Statement
of Organization, Functions and Delegations of Authority for the
Department of Health and Human Services (35 FR 3685, February 25, 1970,
60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112,
August 30, 2007, 74 FR 41713, August 18, 2009, 76 FR 45270, July 28,
2011, and 84 FR 22854, May 20, 2019) is amended to reflect the
reorganization of the CDRH OCE.
The reorganization of OPEQ impacted the OPEQ's Office of Clinical
Evidence and Analysis (OCEA) and the OPEQ's Office of Health Technology
IV (OHT IV). OCEA established the Division of Clinical Evidence and
Analysis IV and the Division of Clinical Evidence and Analysis V. OHT
IV established the Division of Health Technology IV C.
DCCFB. ORGANIZATION. CDRH's OPEQ OCEA is headed by the Director,
and includes the following:
Office of Clinical Evidence and Analysis (DCCFB)
Division of Clinical Evidence and Analysis I (DCCFBA)
Division of Clinical Evidence and Analysis II (DCCFBB)
Division of Clinical Evidence and Analysis III (DCCFBC)
Division of Clinical Evidence and Analysis IV (DCCFBD)
Division of Clinical Evidence and Analysis V (DCCFBE)
DCCFF. ORGANIZATION. CDRH's OPEQ OHT IV is headed by the Director,
and includes the following:
Office of Health Technology IV (DCCFF)
Division of Health Technology IV A (DCCFFA)
Division of Health Technology IV B (DCCFFB)
Division of Health Technology IV C (DCCFFC)
II. Delegations of Authority
Pending further delegation, directives, or orders by the
Commissioner of Food and Drugs, all delegations and redelegations of
authority made to officials and employees of affected organizational
components will continue in them or their successors pending further
redelegations, provided they are consistent with this reorganization.
III. Electronic Access
This reorganization is reflected in FDA's Staff Manual Guide (SMG).
Persons interested in seeing the complete SMG can find it on FDA's
website at: https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm.
(Authority: 44 U.S.C. 3101).
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2024-09382 Filed 5-6-24; 8:45 am]
BILLING CODE 4164-01-P
